Cardiovascular disease remains the leading cause of death in people with type 2 diabetes. A new meta-analysis has now pooled the evidence from every major cardiovascular outcome trial of GLP-1 receptor agonists — the class of drugs that includes semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and dulaglutide (Trulicity) — to clarify exactly how much protection these medications offer.
Nine trials, nearly 70,000 participants. Published in Cureus, the systematic review and meta-analysis followed PRISMA 2020 guidelines and included nine randomized, double-blind, placebo-controlled cardiovascular outcome trials (CVOTs) enrolling a total of 69,730 adults with type 2 diabetes. Each trial compared a GLP-1 receptor agonist against placebo and reported adjudicated major adverse cardiovascular events (MACE) — a composite of heart attack, stroke, and cardiovascular death — as a primary or co-primary endpoint.
A 14% reduction in MACE risk. When the nine trials were pooled using a random-effects model, GLP-1 receptor agonists reduced the risk of MACE by 14% compared with placebo (hazard ratio 0.86; 95% confidence interval 0.82–0.92; p < 0.001). The finding was robust: leave-one-out sensitivity analysis produced hazard ratios ranging from 0.85 to 0.88, and no small-study bias was detected (Egger's test p = 0.13).
The benefit was driven by fewer heart attacks and strokes. Hospitalization for heart failure, by contrast, showed a neutral effect — meaning the cardiovascular protection does not appear to operate through improvements in cardiac pumping function but rather through reductions in atherosclerotic events.
Moderate heterogeneity, but the direction was consistent. Statistical heterogeneity among the trials was moderate (I² = 37%) and not statistically significant (Cochran's Q p = 0.12). The GLP-1 receptor agonist group showed a favorable MACE hazard ratio in eight of the nine trials, with individual trial hazard ratios ranging from 0.73 to 1.02; five of the nine reached statistical significance on their own. The 95% prediction interval for the pooled effect was 0.75 to 1.00, meaning future trials of a similar design would be expected to show a benefit — though the upper bound touches the line of no effect.
What the authors found across individual agents. The meta-analysis confirmed that gastrointestinal side effects are the most common class-wide issue, and a signal for increased gallbladder and biliary disease was evident across the class. A diabetic retinopathy signal was noted specifically with subcutaneous semaglutide — a finding that has been observed in prior analyses and warrants monitoring. Eight of the nine trials were judged to be at low risk of bias, and the certainty of evidence was rated as moderate using the GRADE framework.
The broader picture. The analysis supports the current positioning of GLP-1 receptor agonists as a cornerstone of cardiovascular risk management in type 2 diabetes. While the authors note that differences between individual agents and trial designs prevent a definitive ranking of which drug offers the most protection, the class as a whole shows a consistent, clinically meaningful benefit.
Bottom line: In adults with type 2 diabetes, GLP-1 receptor agonists reduce the risk of major cardiovascular events by approximately 14%, driven by fewer heart attacks and strokes, with an acceptable safety profile. The evidence comes from nearly 70,000 participants across nine high-quality randomized trials.
Medical note. This article summarizes peer-reviewed research for general education. It is not personal medical advice. Decisions about diabetes medications should be made with a healthcare provider who knows your full medical history.